Lam Research Corporation
NasdaqGS-LRCX
Company Overview
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products. It also provides SPEED gapfill high-density plasma chemical vapor deposition products; and Striker single-wafer atomic layer deposition products for dielectric film solutions. In addition, the company offers Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. Further, it provides Coronus bevel clean products to enhance die yield; Da Vinci, DV-Prime, EOS, and SP series products to address various wafer cleaning applications; and Metryx mass metrology systems for high precision in-line mass measurement in semiconductor wafer manufacturing. The company sells its products and services to semiconductors industry in the United States, China, Europe, Japan, Korea, Southeast Asia, Taiwan, and internationally. Lam Research Corporation was incorporated in 1980 and is headquartered in Fremont, California.
Name
Lam Research Corporation
CEO
Mr. Timothy M. Archer
Website
www.lamresearch.com
Sector
Semiconductors and Semiconductor Equipment
Year Founded
1980
Profile
Market Cap
$98.17B
EV
$97.59B
Shares Out
129.88M
Revenue
$14.91B
Employees
17,450
Margins
Gross
47.61%
EBITDA
31.43%
Operating
29.02%
Pre-Tax
29.25%
Net
25.68%
FCF
28.55%
Returns (5Yr Avg)
ROA
23.1%
ROTA
60.76%
ROE
59.18%
ROCE
34.82%
ROIC
40.73%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$1,016.6
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$5,847.86M
Net Debt
-$576.81M
Debt/Equity
0.62
EBIT/Interest
23.35
Growth (CAGR)
Rev 3Yr
0.63%
Rev 5Yr
9.08%
Rev 10Yr
12.46%
Dil EPS 3Yr
2.54%
Dil EPS 5Yr
16.18%
Dil EPS 10Yr
23.13%
Rev Fwd 2Yr
17.84%
EBITDA Fwd 2Yr
20.08%
EPS Fwd 2Yr
23.07%
EPS LT Growth Est
15.01%
Dividends
Yield
—
Payout
27.46%
DPS
$8
DPS Growth 3Yr
15.44%
DPS Growth 5Yr
12.7%
DPS Growth 10Yr
46.14%
DPS Growth Fwd 2Yr
5.52%